JP2024511208A5 - - Google Patents
Info
- Publication number
- JP2024511208A5 JP2024511208A5 JP2023559684A JP2023559684A JP2024511208A5 JP 2024511208 A5 JP2024511208 A5 JP 2024511208A5 JP 2023559684 A JP2023559684 A JP 2023559684A JP 2023559684 A JP2023559684 A JP 2023559684A JP 2024511208 A5 JP2024511208 A5 JP 2024511208A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- weight
- basis
- maximum
- weight basis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163166995P | 2021-03-27 | 2021-03-27 | |
| US63/166,995 | 2021-03-27 | ||
| US202263269330P | 2022-03-14 | 2022-03-14 | |
| US63/269,330 | 2022-03-14 | ||
| PCT/EP2022/058180 WO2022207580A2 (en) | 2021-03-27 | 2022-03-28 | Compositions having improved bioavailability of therapeutics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024511208A JP2024511208A (ja) | 2024-03-12 |
| JP2024511208A5 true JP2024511208A5 (cg-RX-API-DMAC10.html) | 2025-04-04 |
Family
ID=81386993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023559684A Pending JP2024511208A (ja) | 2021-03-27 | 2022-03-28 | 治療薬のバイオアベイラビリティを改善した組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12678502B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4312978A2 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024511208A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240021751A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022248850A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3212583A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL306029A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022207580A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8895537B2 (en) * | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating cardiovascular diseases |
| WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
| BR112021013924A2 (pt) | 2019-01-18 | 2021-09-21 | Astrazeneca Ab | Inibidores de pcsk9 e métodos de uso do mesmo |
| AU2022248850A1 (en) | 2021-03-27 | 2023-11-09 | TRx Biosciences Limited | Compositions having improved bioavailability of therapeutics |
| US11992483B2 (en) | 2021-03-31 | 2024-05-28 | Cali Biosciences Us, Llc | Emulsions for local anesthetics |
| WO2023174941A1 (en) * | 2022-03-14 | 2023-09-21 | TRx Biosciences Limited | Fibrate compositions for treating inflammation and neuroinflammation |
| WO2024123935A2 (en) * | 2022-12-07 | 2024-06-13 | Freedom Biosciences, Inc. | Treatment or prevention of depressive disorders through combination therapy |
| WO2025093572A1 (en) * | 2023-10-29 | 2025-05-08 | TRx Biosciences Limited | Solid dispersion compositions and uses thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5082667A (en) | 1988-06-07 | 1992-01-21 | Abbott Laboratories | Solid pharmaceutical dosage in tablet triturate form and method of producing same |
| US5885486A (en) | 1993-03-05 | 1999-03-23 | Pharmaciaand Upjohn Ab | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof |
| CA2091152C (en) * | 1993-03-05 | 2005-05-03 | Kirsten Westesen | Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof |
| US20020028813A1 (en) | 1997-09-03 | 2002-03-07 | Paul F. Jackson | Thioalkyl compounds, methods, and compositions for inhibiting parp activity |
| US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US6719999B2 (en) | 1999-03-31 | 2004-04-13 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
| US6982281B1 (en) | 2000-11-17 | 2006-01-03 | Lipocine Inc | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| US6762203B2 (en) * | 1999-08-03 | 2004-07-13 | Kao Corporation | Oil composition |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| JP3769203B2 (ja) * | 2001-03-26 | 2006-04-19 | 花王株式会社 | ペットフード又は飼料 |
| EP1706098A4 (en) | 2003-11-26 | 2012-08-15 | Supernus Pharmaceuticals Inc | MICRO-LAYER SYSTEMS FOR THE TRANSPORT OF LIPOPHILES AND BZW. HYDROPHOBIC COMPOUNDS |
| WO2006017692A2 (en) | 2004-08-06 | 2006-02-16 | Transform Pharmaceuticals, Inc. | Novel fenofibrate formulations and related methods of treatment |
| US20060138059A1 (en) | 2004-12-28 | 2006-06-29 | Vair Larry L Jr | Corona-treated polypropylene liquid filtration media |
| US9265724B2 (en) * | 2005-11-07 | 2016-02-23 | Ram B. Murty | Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery |
| US20140357708A1 (en) * | 2005-11-07 | 2014-12-04 | Murty Pharmaceuticals, Inc. | Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery |
| JP5758630B2 (ja) | 2007-11-15 | 2015-08-05 | エンメエッセディ・イタリア・エッセ・エッレ・エッレ | Parp阻害剤としてのピリダジノン誘導体 |
| ES2423793T3 (es) | 2008-05-26 | 2013-09-24 | Genfit | Compuestos agonistas de PPAR, preparación y usos para el tratamiento de la diabetes y/o dislipidemias |
| CN101366697A (zh) * | 2008-08-14 | 2009-02-18 | 沈阳万爱普利德医药科技有限公司 | 一种新的包含紫杉醇类物质的注射用纳米脂质载体及其制备方法 |
| EP2346495B2 (en) | 2008-10-07 | 2023-05-24 | Kudos Pharmaceuticals Limited | Pharmaceutical formulation 514 |
| CN102307576A (zh) * | 2008-12-15 | 2012-01-04 | 班纳制药公司 | 用于增强水不溶性活性剂的释放和吸收的方法 |
| CN101507707B (zh) | 2009-04-08 | 2011-01-19 | 邓菊娟 | 一种盐酸法舒地尔脂微球制剂及其制备方法 |
| CN101926757B (zh) | 2010-09-01 | 2013-01-02 | 北京大学 | 一种难溶性药物的液体组合物及其制备方法 |
| WO2012104655A2 (en) | 2011-02-04 | 2012-08-09 | Biocopea Limited | Compostions and methods for treating chronic inflammation and inflammatory diseases |
| JP2014518609A (ja) | 2011-03-03 | 2014-08-07 | テルサス ファーマシューティカルズ リミテッド ライアビリティ カンパニー | C16:1n7−パルミトレアートを含む組成物および方法 |
| CN102813639B (zh) | 2011-06-08 | 2014-04-30 | 中国疾病预防控制中心寄生虫病预防控制所 | 甲苯达唑软胶囊剂 |
| WO2013049749A2 (en) * | 2011-09-29 | 2013-04-04 | Plx Pharma Inc. | pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME |
| US9073944B2 (en) | 2012-02-21 | 2015-07-07 | Merck Patent Gmbh | Cyclic diaminopyrimidine derivatives |
| MX377877B (es) | 2013-01-14 | 2025-03-11 | Infirst Healthcare Ltd | Composiciones de solución sólida y su uso en el tratamiento del dolor intenso. |
| JP6474732B2 (ja) | 2013-01-14 | 2019-02-27 | インファースト ヘルスケア リミテッド | 激痛治療用組成物と方法 |
| CN105120900A (zh) | 2013-02-04 | 2015-12-02 | 因佛斯特医疗有限公司 | 用于治疗慢性炎症和炎性疾病的组合物及方法 |
| US20160000714A1 (en) * | 2013-03-06 | 2016-01-07 | Capsugel Belgium Nv | Curcumin solid lipid particles and methods for their preparation and use |
| AU2014360537B2 (en) | 2013-12-04 | 2017-09-07 | Gilead Sciences, Inc. | Methods for treating cancers |
| CN108025078A (zh) | 2015-08-07 | 2018-05-11 | 因佛斯特医疗有限公司 | 用于nsaid的固体溶液组合物 |
| ES2975417T3 (es) | 2017-03-03 | 2024-07-05 | Inspirna Inc | Formulaciones con estabilidad mejorada |
| AU2019231699B2 (en) | 2018-03-07 | 2023-03-09 | Andrew Xian Chen | Aqueous formulations for insoluble drugs |
| WO2020079706A1 (en) | 2018-10-15 | 2020-04-23 | Cipla Limited | Pharmaceutical formulation |
| WO2020217235A1 (en) | 2019-04-24 | 2020-10-29 | Aizant Drug Research Solutions Private Limited | Solid dosage form of dasatinib |
| WO2020225395A1 (en) * | 2019-05-07 | 2020-11-12 | Bausch Health Ireland Limited | Liquid oral dosage formulations of methylnaltrexone |
| AU2022248850A1 (en) | 2021-03-27 | 2023-11-09 | TRx Biosciences Limited | Compositions having improved bioavailability of therapeutics |
| CN113546045B (zh) | 2021-08-18 | 2022-11-11 | 浙江大学 | 恢复肿瘤微环境失活树突状细胞功能的纳米制剂及应用 |
-
2022
- 2022-03-28 AU AU2022248850A patent/AU2022248850A1/en active Pending
- 2022-03-28 WO PCT/EP2022/058180 patent/WO2022207580A2/en not_active Ceased
- 2022-03-28 JP JP2023559684A patent/JP2024511208A/ja active Pending
- 2022-03-28 CA CA3212583A patent/CA3212583A1/en active Pending
- 2022-03-28 US US17/656,702 patent/US12678502B2/en active Active
- 2022-03-28 IL IL306029A patent/IL306029A/en unknown
- 2022-03-28 KR KR1020237037012A patent/KR20240021751A/ko active Pending
- 2022-03-28 EP EP22718916.4A patent/EP4312978A2/en active Pending
-
2023
- 2023-10-16 US US18/487,486 patent/US12226484B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025509680A5 (cg-RX-API-DMAC10.html) | ||
| JP4790123B2 (ja) | 胆汁酸を有する透明水溶液型製剤の調剤 | |
| JP6474732B2 (ja) | 激痛治療用組成物と方法 | |
| PT2429317T (pt) | Composições ricas em ácidos gordos ómega-3 com um teor baixo de ácido fitânico | |
| BRPI0013939B1 (pt) | Pharmaceutical composition for controlling or avoiding obesity, process for preparing and using the same | |
| JPH0147445B2 (cg-RX-API-DMAC10.html) | ||
| KR100533460B1 (ko) | 난용성 약물의 가용화용 점막흡착성 조성물, 이를 이용한난용성 약물의 가용화용 제형 및 이들의 제조 방법 | |
| CN103957888A (zh) | 用于将药物沿胃肠道靶向释放的pH依赖性载体、其组合物及其制备和应用 | |
| JP2020530464A5 (cg-RX-API-DMAC10.html) | ||
| NO343582B1 (no) | Oral medikamentformulering omfattende ospemifen | |
| EP0246294A1 (en) | USE OF A HYDROPHOBIC SUBSTANCE TO PREPARE AN ENTERIC PREPARATION FOR TREATING OBESITY, AND ENTERIC PREPARATION. | |
| WO2014158256A1 (en) | Omega-3 pentaenoic acid compositions and methods of use | |
| WO2001005406A1 (fr) | Preparations de glycyrrhizine pour absorption par voie transmuqueuse | |
| AU2020361994A1 (en) | Liquid crystalline structure-forming omega-3-fatty acid composition | |
| CN101304738A (zh) | 非培米芬的制剂 | |
| EP3232798A1 (en) | Enhanced omega-3 formulations | |
| JPS61224962A (ja) | 昆布エキス含有カプセル | |
| WO1985004804A1 (fr) | Agent cholagogique/cholelithotriptique | |
| DE19645044A1 (de) | Verwendung von Ursodeoxycholsäure zur topischen Behandlung von Entzündungserkrankungen der Schleimhäute | |
| JP2001513493A (ja) | 経鼻投与用組成物 | |
| JP4794148B2 (ja) | ネフローゼ症候群治療剤 | |
| JP4452970B2 (ja) | ジクロフェナクナトリウム経口製剤 | |
| PT1311260E (pt) | Utilização de inibidores de lipase para o tratamento da dispepsia | |
| US20240316073A1 (en) | Cannabidiolic acid esters for treating prader-willi syndrome | |
| JP2025508890A5 (cg-RX-API-DMAC10.html) |